Fosamax Cost in Arkansas 2026: Alendronate Prices, Medicaid Coverage, and Savings Options

What Does Fosamax Actually Cost in Arkansas in 2026?

Generic alendronate sodium 70 mg tablets cost an average of $15 per month at Arkansas retail pharmacies in 2026 when purchased with a discount card or as a cash-pay patient. Branded Fosamax carries a manufacturer list price near $80 per month, though very few patients pay that amount after insurance or discount programs apply.

The price gap between branded and generic matters in Arkansas because the state has a relatively high rate of uninsured adults. According to the Centers for Disease Control and Prevention, approximately 9.2% of Arkansas adults lacked health insurance as of the most recent survey period, a figure above the national average [1]. For those patients, the $15 generic price represents the most accessible starting point.

Alendronate belongs to the bisphosphonate class of drugs. It inhibits osteoclast-mediated bone resorption, increasing bone mineral density at the spine and hip. The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) found that alendronate 10 mg daily reduced the risk of new vertebral fractures by 47% over three years compared to placebo in postmenopausal women with low bone mineral density (P<0.001) [2]. That clinical record is why it remains the most commonly prescribed oral bisphosphonate in the United States.

Pharmacy-specific pricing varies. GoodRx-indexed prices in Arkansas for a 4-tablet supply (one month) of alendronate 70 mg range from approximately $9 at Walmart and Sam's Club to $18 at independent pharmacies. Walgreens and CVS locations typically fall between $12 and $20 depending on the coupon applied. Prices shift quarterly, so checking the current coupon at the dispensing pharmacy before each fill makes sense.

The table below outlines the three main pricing tiers an Arkansas patient will encounter in 2026.

| Pricing Tier | Monthly Cost (Approx.) | Who Qualifies | |---|---|---| | Medicaid (with PA approval) | $0 to $3 copay | Arkansas Medicaid beneficiaries | | Commercial insurance copay | $0 to $25 | Patients with Part D or employer plan | | Cash pay / discount card | $9 to $20 | Uninsured or underinsured patients | | Branded Fosamax (list price) | ~$80 | Rare; mostly patients with brand-lock coverage | | Compounded 503A (Rx required) | $0 to $15 | Patients with a qualifying compounding order |

Does Arkansas Medicaid Cover Fosamax?

Arkansas Medicaid covers alendronate on its preferred drug list, but prior authorization is required. That prior authorization process is not automatic, and prescribers need to submit documentation before the pharmacy can dispense at the Medicaid rate.

Arkansas's Medicaid pharmacy program, administered through Arkansas DHS Division of Medical Services, places alendronate in a tier requiring PA for most adult beneficiaries. The PA criteria generally require a diagnosis of osteoporosis confirmed by DEXA scan T-score of -2.5 or lower, or documented fragility fracture history. Patients with documented osteopenia (T-score between -1.0 and -2.5) who also have a high FRAX 10-year fracture risk score may also qualify. The National Osteoporosis Foundation clinical practice guideline recommends treatment when the 10-year probability of a major osteoporotic fracture exceeds 20% or hip fracture probability exceeds 3% using the FRAX tool [3].

Arkansas Medicaid members who obtain PA approval typically pay $0 to a small copay under $3 per monthly supply. Members enrolled in Arkansas's Medicaid managed care organizations (including Arkansas Total Care and Help Healthcare Solutions) should verify their specific formulary, since managed care plans may apply different tier placements or step-therapy requirements.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "Bisphosphonates are recommended as first-line pharmacological treatment for women at high risk of fracture" [4]. That guideline language can be used by both prescribers and patients as supporting documentation during the Medicaid PA process.

If PA is denied, patients have the right to appeal through the Arkansas DHS appeals process. A written appeal with clinical notes from the prescribing physician resolves most denials at the first administrative level.

Which Commercial Insurance Plans Cover Alendronate in Arkansas?

Most commercial insurance plans sold through the Arkansas Health Insurance Marketplace cover generic alendronate at low or zero cost, though tier placement determines the exact copay.

Blue Cross and Blue Shield of Arkansas, the largest insurer in the state, places generic alendronate on Tier 1 (preferred generic) of most of its formularies, resulting in a $0 to $10 copay per fill. QualChoice of Arkansas and Ambetter from Home State Health similarly list alendronate as a preferred generic. Federal employee plans (FEHB) uniformly cover it without step therapy.

Medicare Part D coverage in Arkansas places generic alendronate on Tier 1 or Tier 2 for most plans. The average Part D enrollee copay for a Tier 1 generic in 2026 is $0 to $7 at preferred network pharmacies [5]. Branded Fosamax, when it appears on a Part D formulary at all, typically falls on Tier 3 or Tier 4, generating significantly higher cost-sharing. Because the generic is therapeutically equivalent and FDA-rated AB, there is no clinical reason for most patients to choose branded over generic.

Employer-sponsored plans offered through Arkansas employers are not standardized, but ERISA-governed group health plans increasingly use PBM formularies (CVS Caremark, Express Scripts, OptumRx) that place alendronate at Tier 1 with minimal cost-sharing.

For patients who encounter a formulary exception or a gap in coverage, Merck's patient assistance program (Merck Patient Assistance Program, merckhelps.com) provides branded Fosamax at no cost to qualifying uninsured or underinsured patients who meet income thresholds. Income requirements typically fall at or below 200% of the Federal Poverty Level.

Is Compounded Alendronate Legal in Arkansas?

Compounded alendronate is legal in Arkansas when prepared by a state-licensed 503A pharmacy operating under a valid prescription from a licensed prescriber.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. A 503A pharmacy in Arkansas may compound alendronate for an identified individual patient if a licensed prescriber writes a prescription with a documented clinical rationale. Common reasons for compounding include dysphagia (difficulty swallowing standard tablets), documented intolerance to commercial tablet excipients, or the need for a dose not commercially available.

The Arkansas State Board of Pharmacy licenses and inspects compounding pharmacies operating within the state. Out-of-state 503A pharmacies shipping compounded alendronate into Arkansas must be licensed by the Arkansas Board as non-resident pharmacies [6]. Patients should verify that any compounding pharmacy they use holds both an active home-state license and an Arkansas non-resident pharmacy permit before filling.

One practical caution: the FDA has not approved compounded alendronate as a finished drug product. The agency's guidance on compounding states that pharmacies may not compound drugs that are essentially copies of commercially available products for reasons other than a documented clinical difference. A prescriber writing for compounded alendronate should clearly document the clinical need in the patient's chart.

Cost for compounded alendronate varies by formulation and pharmacy, but oral liquid or alternate-strength formulations from 503A pharmacies in Arkansas typically run $0 to $15 per month, and in some cases are covered by flexible spending accounts or health savings accounts as a qualified medical expense.

Can I Get a Fosamax Prescription via Telehealth in Arkansas?

Yes. Arkansas permits telehealth prescribing of alendronate, and as of 2026, state law allows the establishment of a valid prescriber-patient relationship via synchronous video visit.

Arkansas Code Annotated 17-80-117 and the Arkansas Telemedicine Act permit licensed physicians, nurse practitioners, and physician assistants to prescribe Schedule V and non-controlled medications, including alendronate, after conducting a real-time video evaluation. Audio-only telehealth may be used in some circumstances, though prescribers typically require video to conduct an adequate musculoskeletal and fall-risk assessment before initiating bisphosphonate therapy.

HealthRX connects patients in Arkansas with board-certified clinicians who can review DEXA scan results, calculate FRAX scores, and issue an alendronate prescription during a telehealth visit. The American Association of Clinical Endocrinologists (AACE) 2020 clinical practice guidelines on osteoporosis specify that DEXA T-score documentation at the lumbar spine, total hip, or femoral neck is required before initiating pharmacotherapy [7]. Patients should have DEXA results available before or shortly after their telehealth visit.

One Arkansas-specific point: the state requires that telehealth prescribers either hold an active Arkansas license or practice through a qualifying interstate compact arrangement. Verify your telehealth provider's Arkansas licensure before the appointment.

What Are the Cheapest Ways to Get Alendronate in Arkansas?

The lowest cost option for most Arkansas patients without Medicaid is a GoodRx or similar discount card used at Walmart, Sam's Club Pharmacy, or Costco Pharmacy, generating a cash price between $9 and $15 per month for generic alendronate 70 mg.

Ranked by typical out-of-pocket cost for an uninsured Arkansas patient:

1. Walmart $4/$10 generic program: Alendronate 70 mg (4 tablets, 28-day supply) frequently appears on Walmart's $10 monthly generic list at Arkansas locations. No membership required.
2. GoodRx coupon at Sam's Club: Prices at Sam's Club Pharmacy in Little Rock, Fort Smith, and Fayetteville have indexed as low as $9 per fill with GoodRx Gold.
3. NeedyMeds and RxAssist: These non-profit databases aggregate patient assistance programs. Qualifying low-income patients may obtain free alendronate through Merck Helps.
4. Arkansas Medicaid (with PA): Zero to minimal copay once PA is approved, as described above.
5. Compounded alendronate through a 503A pharmacy: Cost depends on formulation but can be lower than retail generic for some specialty preparations.

Patients should avoid purchasing alendronate from non-US online pharmacies. The FDA has issued repeated warnings about counterfeit bisphosphonates sold through unverified international websites [8]. The risks include subpotent doses (meaning patients receive inadequate fracture protection) and contaminated excipients.

How Do Merck and Generic Manufacturer Savings Cards Work in Arkansas?

Merck's copay savings card for branded Fosamax is available to commercially insured patients in Arkansas, but it does not apply to government-funded insurance (Medicaid, Medicare, TRICARE, or VA).

For commercially insured patients, the Merck savings card historically reduces the branded Fosamax copay to $0 to $30 per fill, depending on the program terms in effect for that calendar year. Because generic alendronate costs less than the savings-card-adjusted branded price at most Arkansas pharmacies, the card's practical value is limited to patients whose insurance covers only the brand and not the generic, a relatively uncommon situation.

Generic alendronate manufacturers (Teva, Mylan, Amneal, and others) do not routinely offer manufacturer rebate cards for their generic versions. Instead, third-party coupon platforms do the work. GoodRx, RxSaver, Blink Health, and Cost Plus Drugs (Mark Cuban's pharmacy) all negotiate prices with pharmacy benefit networks and pass savings to the patient at the point of sale. Cost Plus Drugs listed alendronate 70 mg at $8.30 per month as of mid-2025, which is accessible to Arkansas patients through mail order.

The Inflation Reduction Act's Medicare drug price negotiation provisions did not include alendronate in the first two negotiation cycles (2026 and 2027), since generic competition already keeps the price below the threshold that triggers negotiation. Still, Medicare Part D plans in Arkansas have voluntarily placed generic alendronate at $0 copay on several benchmark plans.

What Clinical Evidence Supports Using Alendronate Long-Term?

Alendronate's fracture-reduction evidence is among the most replicated in osteoporosis pharmacology, spanning more than 25 years of published data.

The FIT trial (JAMA 1998, N=2,027) remains the foundation. Postmenopausal women with at least one existing vertebral fracture were randomized to alendronate 5 mg daily (later 10 mg daily) or placebo. Over three years, the alendronate group showed a 47% relative risk reduction in new morphometric vertebral fractures and a 51% reduction in clinical vertebral fractures (P<0.001) [2]. Hip fracture risk fell by 51% in the active treatment arm.

The FLEX trial (JAMA 2006, N=1,099) addressed how long patients should continue therapy. Women who had taken alendronate for five years were randomized to continue for an additional five years or switch to placebo. Continued alendronate produced meaningfully higher bone mineral density at the femoral neck compared to discontinuation, though the between-group difference in non-vertebral fracture risk did not reach statistical significance over the five-year extension [9]. That finding informs current guideline recommendations for a "drug holiday" after three to five years of treatment in lower-risk patients, while higher-risk patients continue beyond five years.

The American Society for Bone and Mineral Research task force recommends reassessing fracture risk after three to five years of bisphosphonate therapy and considering a drug holiday for patients whose hip T-score has risen above -2.5 and who have not had a hip or vertebral fracture during treatment [10]. Conversely, patients with a T-score that remains below -2.5 or who have had a fracture on therapy should continue treatment or transition to an anabolic agent.

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) are the two serious adverse events associated with long-term bisphosphonate use. Both are rare. The incidence of AFF in patients taking alendronate for five or more years is estimated at 3.2 to 50 cases per 100,000 person-years, depending on duration, compared to a background rate of roughly 1.8 per 100,000 person-years [11]. ONJ incidence in oral bisphosphonate users (as opposed to intravenous bisphosphonate recipients) is estimated at fewer than 1 case per 10,000 patient-years in the absence of major dental procedures [12]. These figures should be contextualized against the substantial fracture risk reduction, particularly in patients with established osteoporosis.

Dosing, Administration, and Practical Considerations for Arkansas Patients

Alendronate is taken as a single 70 mg oral tablet once weekly for osteoporosis treatment, or 35 mg once weekly for osteoporosis prevention. The 10 mg daily regimen is less commonly prescribed now that the once-weekly formulation is available and produces equivalent efficacy data.

Administration requires specific technique. The tablet must be swallowed whole with 6 to 8 ounces of plain water (not coffee, juice, or mineral water) upon waking, at least 30 minutes before any food, drink, or other medication. The patient must remain upright (sitting or standing) for at least 30 minutes after swallowing to minimize the risk of esophageal irritation, which is the most common reason for discontinuation. FDA prescribing information for alendronate states: "Instruct patients that failure to follow these instructions may increase their risk of esophageal problems" [13].

Renal function matters. Alendronate is contraindicated in patients with creatinine clearance below 35 mL/min. Arkansas clinicians managing older rural patients, who may have undiagnosed chronic kidney disease, should obtain a baseline creatinine before prescribing.

Serum calcium and 25-hydroxyvitamin D levels should be adequate before starting. The National Osteoporosis Foundation recommends 1,000 to 1 to 200 mg daily elemental calcium through diet or supplement combined with 800 to 1 to 000 IU daily vitamin D3 for patients on bisphosphonate therapy [3]. Severe vitamin D deficiency (25-OH-D below 20 ng/mL) must be corrected first to avoid hypocalcemia after the first dose.